Pharmaceutical Companies

Once fully operational, the hub is expected to enable access to treatment for more than 2.6 million patients across a population of more than 1 billion people.

Since December 2025, CBC Group, together with the company’s directors have cumulatively purchased more than 3.062 million shares in the open market, amounting to over HK$113.8 million (US$14.56 million).

Idefirix is a first-in-class treatment designed to help highly sensitised adult kidney transplant patients who face difficulties finding compatible donors.

Yuhan operates two API manufacturing facilities in South Korea and has reported steady international growth, with overseas sales increasing 21% in the first quarter.

Owen Mumford brings established expertise in device design, precision moulding, and medical device assembly, which will now be integrated with Embecta’s commercial infrastructure and large-scale manufacturing capabilities.

The company’s presentations at EASL 2026 build on results from the Phase 3 ESSENCE programme, where semaglutide 2.4 mg previously demonstrated significant reductions in liver inflammation and fibrosis among patients with MASH.

Under the licensing arrangement, the Medicines Patent Pool (MPP) has invited qualified generic drug manufacturers to submit applications to produce generic versions of Xofluza.

Under the collaboration, the companies will evaluate Helicons both as standalone therapies and as payloads linked to Regeneron antibodies.

The JV combines Arna Pharma’s formulation development expertise and portfolio expansion strategy with Slate Run Pharmaceuticals’ established US commercial operations, regulatory capabilities, and supply chain infrastructure.

The antiviral drug was originally designed to treat influenza but has also attracted attention for its potential activity against other RNA viruses.